JPH09507028A - イエルシニア ペスチス （Ｙｅｒｓｉｎｉａ ｐｅｓｔｉｓ）感染から防御するための生細菌ベクターを含むワクチン組成物 - Google Patents
イエルシニア ペスチス （Ｙｅｒｓｉｎｉａ ｐｅｓｔｉｓ）感染から防御するための生細菌ベクターを含むワクチン組成物Info
- Publication number
- JPH09507028A JPH09507028A JP7517658A JP51765895A JPH09507028A JP H09507028 A JPH09507028 A JP H09507028A JP 7517658 A JP7517658 A JP 7517658A JP 51765895 A JP51765895 A JP 51765895A JP H09507028 A JPH09507028 A JP H09507028A
- Authority
- JP
- Japan
- Prior art keywords
- microorganism
- plasmid
- recombinant dna
- dna
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229960005486 vaccine Drugs 0.000 title claims abstract description 24
- 239000013598 vector Substances 0.000 title claims description 13
- 239000000203 mixture Substances 0.000 title abstract description 6
- 206010035148 Plague Diseases 0.000 title description 12
- 230000001580 bacterial effect Effects 0.000 title description 2
- 244000005700 microbiome Species 0.000 claims abstract description 54
- 239000013612 plasmid Substances 0.000 claims abstract description 32
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 30
- 241001465754 Metazoa Species 0.000 claims abstract description 29
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 25
- 210000000936 intestine Anatomy 0.000 claims abstract description 13
- 230000028993 immune response Effects 0.000 claims abstract description 12
- 239000000427 antigen Substances 0.000 claims abstract description 9
- 108091007433 antigens Proteins 0.000 claims abstract description 9
- 102000036639 antigens Human genes 0.000 claims abstract description 9
- 241000293869 Salmonella enterica subsp. enterica serovar Typhimurium Species 0.000 claims abstract description 8
- 230000001131 transforming effect Effects 0.000 claims abstract description 5
- 241001467018 Typhis Species 0.000 claims abstract 2
- 108020004511 Recombinant DNA Proteins 0.000 claims description 30
- 241000607479 Yersinia pestis Species 0.000 claims description 27
- 101150033549 caf1 gene Proteins 0.000 claims description 23
- 101100394265 Schizosaccharomyces pombe (strain 972 / ATCC 24843) hba1 gene Proteins 0.000 claims description 17
- 101150052693 cnot7 gene Proteins 0.000 claims description 17
- 108020004414 DNA Proteins 0.000 claims description 15
- 241000282412 Homo Species 0.000 claims description 14
- 239000012634 fragment Substances 0.000 claims description 12
- 230000001681 protective effect Effects 0.000 claims description 12
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 5
- 230000002238 attenuated effect Effects 0.000 claims description 5
- 101150066555 lacZ gene Proteins 0.000 claims description 4
- 241000607142 Salmonella Species 0.000 claims description 3
- 101150052859 Slc9a1 gene Proteins 0.000 claims description 2
- 239000013611 chromosomal DNA Substances 0.000 claims description 2
- 201000010099 disease Diseases 0.000 claims description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 101150110719 caf1A gene Proteins 0.000 claims 1
- 101150042274 caf1M gene Proteins 0.000 claims 1
- 238000011144 upstream manufacturing Methods 0.000 claims 1
- 230000000968 intestinal effect Effects 0.000 abstract description 3
- 238000012217 deletion Methods 0.000 abstract description 2
- 230000037430 deletion Effects 0.000 abstract description 2
- 229940031567 attenuated vaccine Drugs 0.000 abstract 1
- 235000018102 proteins Nutrition 0.000 description 19
- 238000003752 polymerase chain reaction Methods 0.000 description 13
- 241000699670 Mus sp. Species 0.000 description 11
- 241000588724 Escherichia coli Species 0.000 description 9
- 108091034117 Oligonucleotide Proteins 0.000 description 8
- 230000004927 fusion Effects 0.000 description 8
- 108010076504 Protein Sorting Signals Proteins 0.000 description 7
- 238000000034 method Methods 0.000 description 7
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 6
- 230000003321 amplification Effects 0.000 description 6
- 230000000875 corresponding effect Effects 0.000 description 6
- 238000003199 nucleic acid amplification method Methods 0.000 description 6
- 208000015181 infectious disease Diseases 0.000 description 5
- 229920001817 Agar Polymers 0.000 description 4
- 101100273026 Yersinia pestis caf1R gene Proteins 0.000 description 4
- 235000010419 agar Nutrition 0.000 description 4
- 210000002421 cell wall Anatomy 0.000 description 4
- 238000004520 electroporation Methods 0.000 description 4
- 230000036039 immunity Effects 0.000 description 4
- 230000003053 immunization Effects 0.000 description 4
- 238000002649 immunization Methods 0.000 description 4
- 210000004185 liver Anatomy 0.000 description 4
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 3
- 108700026244 Open Reading Frames Proteins 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 101100494490 Yersinia pestis caf1A gene Proteins 0.000 description 3
- 239000008272 agar Substances 0.000 description 3
- 230000029087 digestion Effects 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 238000011081 inoculation Methods 0.000 description 3
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 3
- 238000001262 western blot Methods 0.000 description 3
- 241001167018 Aroa Species 0.000 description 2
- 101100216993 Bacillus subtilis (strain 168) aroD gene Proteins 0.000 description 2
- 108020004705 Codon Proteins 0.000 description 2
- 101100491986 Emericella nidulans (strain FGSC A4 / ATCC 38163 / CBS 112.46 / NRRL 194 / M139) aromA gene Proteins 0.000 description 2
- 241000293871 Salmonella enterica subsp. enterica serovar Typhi Species 0.000 description 2
- 101100494506 Yersinia pestis caf1M gene Proteins 0.000 description 2
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 2
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 2
- 229960000723 ampicillin Drugs 0.000 description 2
- 101150037081 aroA gene Proteins 0.000 description 2
- 101150042732 aroC gene Proteins 0.000 description 2
- 244000052616 bacterial pathogen Species 0.000 description 2
- 244000309464 bull Species 0.000 description 2
- AIYUHDOJVYHVIT-UHFFFAOYSA-M caesium chloride Chemical compound [Cl-].[Cs+] AIYUHDOJVYHVIT-UHFFFAOYSA-M 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 229940030156 cell vaccine Drugs 0.000 description 2
- 210000000349 chromosome Anatomy 0.000 description 2
- 230000001086 cytosolic effect Effects 0.000 description 2
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 2
- 238000010369 molecular cloning Methods 0.000 description 2
- 239000002773 nucleotide Substances 0.000 description 2
- 125000003729 nucleotide group Chemical group 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 239000002953 phosphate buffered saline Substances 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 1
- 241000283074 Equus asinus Species 0.000 description 1
- 241000206672 Gelidium Species 0.000 description 1
- 101000740205 Homo sapiens Sal-like protein 1 Proteins 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 239000006137 Luria-Bertani broth Substances 0.000 description 1
- 108010006519 Molecular Chaperones Proteins 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 102100037204 Sal-like protein 1 Human genes 0.000 description 1
- 241000607734 Yersinia <bacteria> Species 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 102000005936 beta-Galactosidase Human genes 0.000 description 1
- 108010005774 beta-Galactosidase Proteins 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 229940041514 candida albicans extract Drugs 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000004665 defense response Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- RWYFURDDADFSHT-RBBHPAOJSA-N diane Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1.C1=C(Cl)C2=CC(=O)[C@@H]3CC3[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(C)=O)(OC(=O)C)[C@@]1(C)CC2 RWYFURDDADFSHT-RBBHPAOJSA-N 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- BTIJJDXEELBZFS-QDUVMHSLSA-K hemin Chemical compound CC1=C(CCC(O)=O)C(C=C2C(CCC(O)=O)=C(C)\C(N2[Fe](Cl)N23)=C\4)=N\C1=C/C2=C(C)C(C=C)=C3\C=C/1C(C)=C(C=C)C/4=N\1 BTIJJDXEELBZFS-QDUVMHSLSA-K 0.000 description 1
- 229940025294 hemin Drugs 0.000 description 1
- 230000008348 humoral response Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 208000028774 intestinal disease Diseases 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 231100000636 lethal dose Toxicity 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- FRZJZRVZZNTMAW-UHFFFAOYSA-N n,n-diethyl-3-(hydroxymethyl)benzamide Chemical compound CCN(CC)C(=O)C1=CC=CC(CO)=C1 FRZJZRVZZNTMAW-UHFFFAOYSA-N 0.000 description 1
- 230000000242 pagocytic effect Effects 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 210000001539 phagocyte Anatomy 0.000 description 1
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 235000004252 protein component Nutrition 0.000 description 1
- 108010009004 proteose-peptone Proteins 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 102220201851 rs143406017 Human genes 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 238000009589 serological test Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000002627 tracheal intubation Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 230000001018 virulence Effects 0.000 description 1
- 239000012130 whole-cell lysate Substances 0.000 description 1
- 239000012138 yeast extract Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- Oncology (AREA)
- General Chemical & Material Sciences (AREA)
- Physics & Mathematics (AREA)
- Communicable Diseases (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB9326425.7 | 1993-12-24 | ||
| GB939326425A GB9326425D0 (en) | 1993-12-24 | 1993-12-24 | Vaccine compositions |
| PCT/GB1994/002818 WO1995018231A1 (en) | 1993-12-24 | 1994-12-23 | Vaccine compositions comprising live bacterial vectors for protection against yersinia pestis injection |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JPH09507028A true JPH09507028A (ja) | 1997-07-15 |
Family
ID=10747201
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP7517658A Pending JPH09507028A (ja) | 1993-12-24 | 1994-12-23 | イエルシニア ペスチス （Ｙｅｒｓｉｎｉａ ｐｅｓｔｉｓ）感染から防御するための生細菌ベクターを含むワクチン組成物 |
Country Status (6)
| Country | Link |
|---|---|
| EP (1) | EP0741786A1 (de) |
| JP (1) | JPH09507028A (de) |
| AU (1) | AU1322295A (de) |
| CA (1) | CA2179639A1 (de) |
| GB (1) | GB9326425D0 (de) |
| WO (1) | WO1995018231A1 (de) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20070043215A1 (en) * | 1996-08-27 | 2007-02-22 | Heath David G | Recombinant f1-v plague vaccine |
| WO1998024912A2 (en) * | 1996-12-04 | 1998-06-11 | Heska Corporation | Recombinant plague vaccine |
| EP1176966B1 (de) * | 1999-04-12 | 2013-04-03 | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | Oligodeoxynukleotide und deren verwendung zur induktion einer immunreaktion |
| GB9921275D0 (en) * | 1999-09-10 | 1999-11-10 | Secr Defence | Recombinant microorganisms |
| ATE378348T1 (de) | 2000-01-14 | 2007-11-15 | Us Health | Oligodeoxynukleotide und ihre verwendung zur induktion einer immunreaktion |
| GB0220257D0 (en) | 2002-08-31 | 2002-10-09 | Secr Defence | Vaccine |
| US7344718B2 (en) | 2003-01-31 | 2008-03-18 | University Of North Dakota | Yersinia species compositions |
| WO2012178078A2 (en) | 2011-06-22 | 2012-12-27 | University Of North Dakota | Use of yscf, truncated yscf and yscf homologs as adjuvants |
| EP2852405B1 (de) | 2012-05-23 | 2019-03-13 | The United States of America, as represented by The Secretary, Department of Health and Human Services | Salmonella typhi ty21a zur expression eines yersinia pestis f1-v-fusionsproteins und verwendungen davon |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0474891A1 (de) * | 1990-09-08 | 1992-03-18 | BEHRINGWERKE Aktiengesellschaft | Vektoren für die Expression malarialer Antigene an der Oberfläche von Salmonella Vakzinstämmen |
| DK0556333T3 (da) * | 1990-11-09 | 2003-07-14 | Univ Washington | Avirulente Salmonella mikrober, der omfatter en mutation i cdt genet, og anvendelser deraf |
-
1993
- 1993-12-24 GB GB939326425A patent/GB9326425D0/en active Pending
-
1994
- 1994-12-23 CA CA002179639A patent/CA2179639A1/en not_active Abandoned
- 1994-12-23 EP EP95904620A patent/EP0741786A1/de not_active Withdrawn
- 1994-12-23 WO PCT/GB1994/002818 patent/WO1995018231A1/en not_active Application Discontinuation
- 1994-12-23 AU AU13222/95A patent/AU1322295A/en not_active Abandoned
- 1994-12-23 JP JP7517658A patent/JPH09507028A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU1322295A (en) | 1995-07-17 |
| WO1995018231A1 (en) | 1995-07-06 |
| CA2179639A1 (en) | 1995-07-06 |
| GB9326425D0 (en) | 1994-02-23 |
| EP0741786A1 (de) | 1996-11-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Poirier et al. | Protective immunity evoked by oral administration of attenuated aroA Salmonella typhimurium expressing cloned streptococcal M protein. | |
| JP5566684B2 (ja) | Ｃｌｏｓｔｒｉｄｉｕｍｄｉｆｆｉｃｉｌｅに対する、組換え毒素Ａ／毒素Ｂワクチン | |
| Sjöstedt et al. | Humoral and cell-mediated immunity in mice to a 17-kilodalton lipoprotein of Francisella tularensis expressed by Salmonella typhimurium | |
| US4888170A (en) | Vaccines obtained from antigenic gene products of recombinant genes | |
| Oyston et al. | Immunization with live recombinant Salmonella typhimurium aroA producing F1 antigen protects against plague | |
| EP0558631B1 (de) | Rekombinante avirulente salmonella antifruchtbarkeitsimpfstoffe | |
| JP4179627B2 (ja) | コレラワクチンとしての欠失変異体 | |
| US20050260223A1 (en) | Salmonella vaccine materials and methods | |
| JP2793673B2 (ja) | 組み換えフラジエリンのワクチン | |
| CA1338705C (en) | Vaccines obtained from antigenic gene products of recombinant genes | |
| WO1988009669A1 (en) | Avirulent microbes and uses therefor | |
| Cárdenas et al. | Stability, immunogenicity and expression of foreign antigens in bacterial vaccine vectors | |
| JP4583607B2 (ja) | 感染症の治療のための弱毒化微生物 | |
| JP6329544B2 (ja) | 新規生弱毒化赤痢菌属（Ｓｈｉｇｅｌｌａ）ワクチン | |
| AU2001256957A1 (en) | Salmonella vaccine materials and methods | |
| US4761372A (en) | Mutant enterotoxin of E. coli | |
| US6939548B2 (en) | Methods to produce high levels of C. difficile toxins | |
| US4935364A (en) | Method of isolating restriction fragment deletions in vibrio cholerae and products thereof | |
| JPH09507028A (ja) | イエルシニア ペスチス （Ｙｅｒｓｉｎｉａ ｐｅｓｔｉｓ）感染から防御するための生細菌ベクターを含むワクチン組成物 | |
| US5135862A (en) | Method of isolating restriction fragment deletions in vibrio cholerae, products thereof | |
| Sory et al. | Yersinia enterocolitica O: 9 as a potential live oral carrier for protective antigens | |
| WO2003041734A1 (en) | Salmonella vaccine | |
| US5874088A (en) | Deletion mutants of cholera vaccines expressing heterologous antigens | |
| EP0485591B1 (de) | Verfahren zum isolieren von vibrio cholerae-deletionsmutanten und vibrio cholerae enthaltende kulturen | |
| RU2140981C1 (ru) | Авирулентный штамм vibrio cholerae не-01 серогруппы (варианты), способ получения штамма (варианты), вакцина |